These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 14668701

  • 1. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors.
    Edelman SV.
    Rev Cardiovasc Med; 2003; 4 Suppl 6():S29-37. PubMed ID: 14668701
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB.
    Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
    [Abstract] [Full Text] [Related]

  • 6. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
    Fonseca VA.
    Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
    [Abstract] [Full Text] [Related]

  • 7. Role of thiazolidinediones in the management of type 2 diabetes: focus on ethnic minority populations.
    Umpierrez G, Dagogo-Jack S.
    Ethn Dis; 2006 Sep; 16(1):51-7. PubMed ID: 16599348
    [Abstract] [Full Text] [Related]

  • 8. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W.
    Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
    [Abstract] [Full Text] [Related]

  • 9. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A.
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Potential cardiovascular benefits of insulin sensitizers.
    Kunhiraman BP, Jawa A, Fonseca VA.
    Endocrinol Metab Clin North Am; 2005 Mar; 34(1):117-35. PubMed ID: 15752925
    [Abstract] [Full Text] [Related]

  • 15. Diabetes and cardiovascular risk markers.
    Erdmann E.
    Curr Med Res Opin; 2005 Mar; 21 Suppl 1():S21-8. PubMed ID: 15811196
    [Abstract] [Full Text] [Related]

  • 16. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.
    Stafylas PC, Sarafidis PA, Lasaridis AN.
    Int J Cardiol; 2009 Jan 24; 131(3):298-304. PubMed ID: 18684530
    [Abstract] [Full Text] [Related]

  • 17. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
    Nesto R.
    Diabet Med; 2004 Aug 24; 21(8):810-7. PubMed ID: 15270782
    [Abstract] [Full Text] [Related]

  • 18. Pleiotropic effects of thiazolidinediones.
    Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS.
    Expert Opin Pharmacother; 2008 May 24; 9(7):1087-108. PubMed ID: 18422468
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B.
    Curr Med Res Opin; 2006 May 24; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.